Natural killer (NK) cells mediate the early, nonadaptive, responses against virus-, intracellular bacteria-, and parasite-infected cells, 1 and modulate the activity of other effector cells of the adaptive and innate systems of defense. In the mouse, interleukin-12 (IL-12)-induced interferon gamma (IFN-␥) production by mature NK cells 2,3 directs the development of Ag-specific cell-mediated responses to intracellular pathogens, controlling Th1 cell differentiation 4 (reviewed in Trinchieri and Scott 5 and Coffman et al 6 ). NK cells participate in the regulation of myeloid hematopoiesis, 7 and activation of myeloid 8 and monocytic cells (reviewed in Trinchieri et al 9 ) via production of granulocyte macrophage-colonystimulating factor (GM-CSF), IL-3, IFN-␥ and tumor necrosis factor alpha (TNF-␣). 10-14 They have also been proposed to participate in the regulation of humoral immune responses, 15, 16 and to play a significant role in the asthma-associated eosinophilia 17, 18 via IL-5 production, and possibly other factors. A minor subset or subsets of IL-13 19 and of IL-5 producing NK cells exists in adult peripheral and umbilical cord blood. 20, 21 Whether combinations of different cytokines are produced by NK cells at distinct stages of differentiation or by distinct mature NK cell subsets remains to be established.
Introduction
Natural killer (NK) cells mediate the early, nonadaptive, responses against virus-, intracellular bacteria-, and parasite-infected cells, 1 and modulate the activity of other effector cells of the adaptive and innate systems of defense. In the mouse, interleukin-12 (IL-12)-induced interferon gamma (IFN-␥) production by mature NK cells 2, 3 directs the development of Ag-specific cell-mediated responses to intracellular pathogens, controlling Th1 cell differentiation 4 (reviewed in Trinchieri and Scott 5 and Coffman et al 6 ). NK cells participate in the regulation of myeloid hematopoiesis, 7 and activation of myeloid 8 and monocytic cells (reviewed in Trinchieri et al 9 ) via production of granulocyte macrophage-colonystimulating factor (GM-CSF), IL-3, IFN-␥ and tumor necrosis factor alpha (TNF-␣). [10] [11] [12] [13] [14] They have also been proposed to participate in the regulation of humoral immune responses, 15, 16 and to play a significant role in the asthma-associated eosinophilia 17, 18 via IL-5 production, and possibly other factors. A minor subset or subsets of IL-13 19 and of IL-5 producing NK cells exists in adult peripheral and umbilical cord blood. 20, 21 Whether combinations of different cytokines are produced by NK cells at distinct stages of differentiation or by distinct mature NK cell subsets remains to be established.
NK cell differentiation is controlled by cytokines produced in an intact bone marrow microenvironment 22, 23 (reviewed in Sivakumar et al 24 ). In the murine system, these include Flt-3 ligand 1 (Flt3-L), 25 c-kit ligand (stem cell factor, SCF), 25, 26 and IL-15 25, 27 that act, alone or together, on NK cells at different stages of differentiation. 25 Flt3-L and IL-15 sustain differentiation of human CD34 ϩ bone marrow cells to cells functionally and phenotypically similar to mature peripheral blood NK cells. [28] [29] [30] Produced by stromal and monocytic/myeloid cells, 31 they likely also act in vivo in physiologic conditions (reviewed in Carson and Calgiuri 32 ). Possible differential effects of these cytokines on NK cell differentiation have been analyzed only at very early developmental stages, 30, 33, 34 when NK lineage-specific markers are not yet identifiable.
In rodents (mouse 35, 36 and rat 37 ) and humans [38] [39] [40] [41] [42] IL-2 efficiently substitutes for IL-15 in vitro to support NK cell differentiation from CD34 ϩ or lineage negative (Lin Ϫ ) hematopoietic progenitor cells. We have reported an in vitro model of human NK cell differentiation involving coculture of umbilical cord blood Lin Ϫ hematopoietic progenitor cells with IL-2 and a murine stromal cell line expressing the membrane-bound form of SCF (mSCF). 21 Using this system, we established that expression of CD161 in the absence of other mature NK cell markers defines NK cells at a relatively immature stage of differentiation. CD161 ϩ /CD56 Ϫ NK cells mediate TRAIL-L-mediated, but not FasL-mediated or granule exocytosis-mediated cytotoxicity, 43 and do not express IFN-␥ upon stimulation. 21 However, in culture conditions including IL-12 and feeder cells, a proportion of these cells is induced to differentiate to mature cells expressing CD56 and, constitutively, IFN-␥ mRNA. 21 It is currently not known whether NK cells at this stage of differentiation produce IFN-␥ or other cytokines produced by mature NK cell subsets or if they can be induced to produce them when cultured with the cytokines we have previously shown able to induce expression of IFN-␥ mRNA.
Here, we have analyzed cytokine production in human NK cells at distinct stages of differentiation. Our data demonstrate that most CD161 ϩ /CD56 Ϫ immature NK cells produce IL-13, TNF-␣, and GM-CSF and contain a minor fraction, undetectable in the mature CD161 ϩ /CD56 ϩ cells, that produces IL-5. As previously suggested based on mRNA expression, the ability to produce IFN-␥ is acquired late, approximately at the same time as acquisition of CD56 expression. Interestingly, late differentiation is concurrent with decreased ability to produce IL-13 and/or IL-5 only, and with the appearance of IFN-␥/IL-13 (or IL-5) double-positive, CD56 Ϫ/dim cells. The data support the conclusion that production of type 2 (IL-13 and IL-5) cytokines is transient and defines an intermediate stage of NK cell differentiation in this in vitro system. This is unlike production of TNF-␣ and GM-CSF, which are produced throughout differentiation.
Materials and methods

Monoclonal and polyclonal antibodies
Monoclonal antobodies (mAbs) to CD2 (B67.1, B67.6), CD4 (B66.6), CD5 (B36.1), CD8 (B116.1), CD11b (B43.4), CD14 (B52.1), CD15 (B40.9), 44 CD16 (3G8), 45 CD56 (B159.5), 44 CD161/NKR-P1A (B199.2), 21 TNF-␣ (B154.1, B154.9, nonneutralizing; B154.2, B154.7, neutralizing), 10 and IFN-␥ (B133.1, B133.3, neutralizing) 46 were previously characterized in our laboratory. mAbs to CD3 (OKT3), CD21 (THB5), CD32 (IV.3), CD34 (My10), CD64 (32.2), and the irrelevant P3 ϫ 63-Ag8.653 Ig were produced from cells obtained from the American Type Culture Collection (ATCC, Rockville, MD). mAb to CD94/NKG2 (HP-3B1) 47, 48 was kindly provided by Dr M. Lopez-Botet (Pompeu Fabra University, Barcelona, Spain). When indicated, mAbs were labeled with biotin or fluorescein isothiocyanate (FITC) according to standard procedures, after purification on protein G-Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden). Phycoerythrin (PE)-anti-CD56 (N901) and electron coupled dye (ECD)-anti-CD3 (UCHT1) were from Coulter (Beckman Immunotec, Marseille, France). FITC-anti-IFN-␥ (B27), FITC-anti-GM-CSF (BVD2-21C11), FITC-anti-CD3 (S4.1), FITC-control mouse IgG1, and PE-anti-TNF-␣ (MP9-20A4) were from Caltag Laboratories (Burlingame, CA); PE-anti-IL-5 (TRFK5 or JES1-39D10), PE-anti-IL-13 (JES10-5A2) (the only available reagents to these cytokines), PE-rat IgG2a (R35-95) and PE-rat IgG1 (R3-34) were from Pharmingen (San Diego, CA). FITC-goat F(abЈ) 2 -anti-mouse F(abЈ) 2 (GaMIg) (Cappel Laboratories, Durham NC) was used for indirect immunofluorescence, and the GaMIgs (produced in our laboratory) used for panning were adsorbed on human Ig-purified and affinity-purified mouse Ig-Sepharose before use. The rabbit IgG anti-sheep erythrocytes (E) used to prepare immune complex monolayers was from Organon-Teknika (Cappel).
Cell isolation
Lymphocytes were isolated from umbilical cord blood samples (provided by Dr R. Wapner, Department of Obstetrics and Gynecology, Thomas Jefferson University Hospital, Philadelphia, PA) collected at delivery from full-term pregnancies, and anticoagulated with heparin. Lin Ϫ cells were purified according to our previously published protocol 21 after sequential depletion of (1) aminoethylisothiouronium bromide (AET)-E rosetting cells (AET, Sigma Chemical); (2) Fc␥R ϩ cells on rabbit IgG immune complex monolayers; and (3) most other mature leukocytes following panning (30 minutes, 4°C) on GaMIg-treated dishes after sensitization of the cells with the panel of mAbs to differentiation antigens on mature hematopoietic cells listed above. The Lin Ϫ cells were more than 99% CD3 Ϫ /CD161 Ϫ /CD16 Ϫ / CD56 Ϫ in immunofluorescence analysis; they were not cytotoxic, and did not express CD16 mRNA, as determined using reverse transcription polymerase chain reaction (RT-PCR) 21 (and data not shown). When indicated, CD34 ϩ cells were positively selected from cells at step (3) after sensitization with anti-CD34 (My10) mAb and panning as above.
Homogeneous immature CD161 ϩ /CD56 Ϫ NK cell populations used in secondary cultures (see below) were purified from 30-day cultures of Lin Ϫ cells with IL-2 depleting (panning or fluorescence-activated cell sorting) CD3 ϩ /CD5 ϩ T cells (if needed), CD32 ϩ /CD64 ϩ myeloid cells, and CD94 ϩ /CD56 ϩ mature NK cells after sensitizing the cells with a panel of mAbs to the indicated surface antigens. These cell populations were more than 99% CD3 Ϫ /CD161 ϩ /CD56 Ϫ in direct immunofluorescence. When indicated, total cell populations from primary cultures, and homogeneous NK cell populations from 10-day cultures of umbilical cord blood lymphocytes with 50 Gy irradiated RPMI-8866 cells as described, 44 were used as a source of NK cells. The latter are referred to as 10-day NK cells. (30 Gy) . Alternatively, Flt-3/Flk-2 ligand (5 ng/mL; specific activity 3 ϫ 10 6 U/mg; R&D Systems, Minneapolis, MN) was used in a feeder cell-free system. rIL-2 (50 U/mL; Hoffman-LaRoche, Nutley, NJ, obtained through the Biological Response Modifiers Program, National Cancer Institute, Bethesda, MD) and rIL-15 (10 ng/mL; specific activity 2.95 ϫ 10 8 U/mg protein; provided by Immunex, Seattle, WA) and/or rIL-12 (2 ng/mL; specific activity 4.5 ϫ 10 6 U/mg protein in an IFN-␥ induction assay; provided by Dr S. Wolf, Genetics Institute, Andover, MA) were added at the beginning of the cultures and every 3 to 4 days during a 20-to 30-day culture period. The culture medium was partially replaced once a week, and nonadherent cells were subcultured when confluent.
Progenitor cell cultures
For secondary cultures, 10 6 unseparated or CD3 Ϫ /CD161 ϩ /CD56 Ϫ NK cells from 30-day primary cultures of Lin Ϫ or CD34 ϩ cells with IL-2 were cultured for 8 to 10 days in 24-well culture plates (2 mL medium/well). rIL-2, rIL-15, rIL-12 (concentrations indicated above), or rIL-4 (10 ng/mL, specific activity Ն 10 7 U/mg protein in a proliferation assay with CTLLhuIL-4R1.d cells; Genzyme, Cambridge, MA) and their combinations were added at the beginning of the culture and every 3 to 4 days. When indicated, 50 Gy-irradiated Daudi cells (5:1 lymphocyte-to-feeder cell ratio), anti-TNF-␣ and/or anti-IFN-␥ mAb (ascites, 1:500 final dilution) were added throughout primary or secondary culture.
Intracellular cytokine detection
Cells were incubated (5 ϫ 10 6 /mL, 6 hours, 37°C) in medium with or without phorbol myristate acetate (PMA) (10 Ϫ9 M) and Ca ϩϩ ionophore (A23187, 0.1 g/mL) (all reagents from Sigma Chemical). Brefeldin A (10 g/mL) was added during the last 3 hours. A Fix/Perm cell permeabilization kit (Caltag Laboratories, Burlingame, CA), or formaldehyde (3.7% in phosphate buffered saline [PBS], 10 minutes, room temperature) and 18-hour incubation in PBS containing 0.5% saponin, 0.2% FBS, 0.005% Tween 20, 0.01% NaN 3 , were used to fix and permeabilize the cells for intracellular cytokine detection combined with surface phenotyping as described in detail. 50 Single-color and multiple-color (up to 4) immunofluorescence analyses (flow cytometry) were performed with the indicated FITC-, PE-, ECD-, or biotin-labeled mAbs, as described. 21 
RT-PCR analyses
These were performed as previously described, 21 using total cellular RNA from cells (5 ϫ 10 5 /sample) incubated (5 ϫ 10 6 /mL, 2 hours, 37°C) in medium with or without combinations of IL-2, IL-12, and IL-15 (50 U/mL, 2 ng/mL, and 10 ng/mL, respectively) for stimulation. The conditions and primers used to detect ␤ actin, IFN-␥, and TNF-␣ mRNA (Clontech Laboratories, Palo Alto, CA) have been reported. 21 The IL-5 and GM-CSF primer sequences used were those defined in a previous report. 51 
Statistical analysis
Data were analyzed using the 2-tailed, paired Student t test (Minitab statistical analysis software, State College, PA). Values of P Ͻ .05 were considered significant.
Results
Kinetics of CD56 ؉ NK cell generation from Lin ؊ cell cultures
The number of CD3 Ϫ /CD56 ϩ NK cells was recorded at different time points during primary cultures of umbilical cord blood Lin Ϫ cells (including CD34 ϩ and CD34 Ϫ cells) with feeder cells and IL-2 or IL-15, alone or combined ( Figure 1 ). Starting on the third week of culture and up to 34 days, at the last time point analyzed, the numbers of CD56 ϩ NK cells generated from cultures with IL-2 and IL-15, IL-2, or IL-15 alone at the doses used were highest, intermediate, and lowest, respectively. The kinetics of generation of NK cells in cultures of CD34 ϩ cells with Flt3-L and IL-2 were similar to those reported in Figure 1 (not shown).
In agreement with our previous data 52 CD3 Ϫ /CD161 ϩ /CD56 ϩ cells were not detected in cultures with IL-12 only, and NK cell generation in cultures with IL-2 or IL-15 was inhibited by IL-12 regardless of the presence of IFN-␥ and/or TNF-␣ neutralizing mAbs (not shown).
CD56 and CD161 expression in NK cells generated from progenitor cell cultures with IL-2 and IL-15
Most CD3 Ϫ /CD161 ϩ cells in primary cultures of Lin Ϫ cells with feeder cells and IL-15 were CD56 ϩ (Figure 2A ). Like the corresponding population in cultures with IL-2 and feeder cells, 21 or Flt3-L and IL-2, variable proportions of these cells (lower than those in mature NK cells from the corresponding cord blood samples) expressed all other mature NK cell markers (CD2, CD8, CD16, CD94, and killer Ig-like receptors, not shown). All CD3 Ϫ / CD56 ϩ cells (herein referred to as CD56 ϩ NK cells) from cultures with IL-2 and Flt3-L, like those from cultures with IL-2 and feeder cells ( Figure 2B and Bennett et al 21 ) , were included in the CD161 ϩ population ( Figure 2C ), as confirmed independently in multiplecolor and single-color immunofluorescence with anti-CD56 mAb alone or combined with anti-CD161 mAb. However, unlike the cultures with IL-15 and feeder cells, both cultures with IL-2 contained a significant proportion (up to 50%) of CD3 Ϫ /CD161 ϩ / CD56 Ϫ cells (herein referred to as CD56 Ϫ NK cells). Most of these immature NK cells 21 expressed CD7 (not shown) and CD161 at an average density higher than that on their CD56 ϩ counterpart ( Figure 2B-C) .
Cytokine production by NK cells derived from progenitor cells
Cytokine expression and surface phenotype were analyzed simultaneously at the single-cell level (multiple-color immunofluorescence, flow cytometry) (Figure 3 ) in cells from primary cultures of (4) IL-2, IL-4, and IL-15 alone support survival/proliferation, but not differentiation, of the CD56 Ϫ NK cells, as indicated by the lack of significant changes in cytokine production in secondary cultures with these cytokines without (this report) or with feeder cells. 21 NK cell differentiation in vivo is mediated, in part, by IL-15, produced by stromal/myeloid cells, 53 and NK cells are not generated in mice lacking IRF-1, 22,23 essential for induced expression of IL-15. In agreement with previous reports using different culture IFN-␥ indicates interferon gamma; GM-CSF, granulocyte macrophage-colony-stimulating factor; TNF-␣, tumor necrosis factor alpha; MFI, mean fluorescence intensity. *The indicated cytokines were added to primary cultures of Lin Ϫ cells with Sl/Sl 4 hSCF 220 feeder cells, as described in "Materials and methods." †Expression of the cytokines listed on top was analyzed (3-color immunofluorescence) in cells stimulated with PMA and Ca 2ϩ ionophore. Analysis was performed on cells gated on the basis of their reactivity with anti-CD161 or anti-CD56 mAb, as described in "Materials and methods," and Figure 3 . ‡Percent positive cells (mean Ϯ SD). §Fluorescence intensity (mean channel of fluorescence, mean Ϯ SD).
Number of experiments. ¶Percentage positive cells in the CD56 Ϫ population significantly different (P Ͻ .05) from that in the CD56 ϩ population. 
IFN-␥ indicates interferon gamma. *Flt3-L and IL-2 were added to primary cultures of CD34 ϩ cells, as described in "Materials and methods." †Expression of the cytokines listed on top was analyzed (4-color immunofluorescence) in cells stimulated as described in "Materials and methods." Analysis was performed on gated CD3 Ϫ /(CD161/CD56) ϩ and CD3 Ϫ /CD56 ϩ cells. The proportion of CD56 ϩ cells within the CD161 ϩ natural killer cells were 40% Ϯ 25% (mean Ϯ SD, n ϭ 3). The proportion of cells producing cytokines within the CD161 ϩ /CD56 Ϫ cells was calculated as described in "Materials and methods." ‡Numbers are percent positive cells (mean Ϯ SD, n ϭ 3). §Percentage positive cells in the CD56 Ϫ population significantly different (P Ͻ .05) from that in the CD56 ϩ population. 
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systems and bone marrow-derived or umbilical cord bloodderived progenitor cells, 27, 28, 30 IL-15 supports the generation of phenotypically mature NK cells in all 3 systems used, and our data show that the relative proportion and phenotype of the cytokineproducing NK cell subsets in either condition are similar to those identified in peripheral blood. However, immature CD161 ϩ / CD56 Ϫ NK cells are not generated in cultures with IL-15. This may depend on the inability of IL-15 to induce their proliferation, and consequent detectable accumulation, whereas IL-2 may be directly or indirectly mitogenic for the same cells. Supporting this possibility, IL-15 maintains the CD161 ϩ /CD56 Ϫ cells without inducing their proliferation in secondary cultures. However, we cannot exclude that IL-15 has a more pronounced differentiation-inducing effect than IL-2, resulting in faster differentiation and consequent difficulty in experimentally identifying cells at intermediate stages of differentiation. Alternatively, progenitor cells at different stages of maturation may be differentially susceptible to the 2 cytokines, like in the murine system, 25, 54 where distinct growth factors act on cells at different stages of maturation. Undefined cytokines contributing to differentiation of earlier NK cell progenitors may be produced endogenously in response to IL-2 by other (eg, myeloid) cells and be depleted at later times during culture, and/or receptors for IL-15 may not be expressed on these cells. Finally, the accumulation of immature NK cells in the cultures with IL-2 may be only apparent and due to susceptibility of the mature cells to death induced by membrane-bound or soluble factors expressed by the NK or other cells in the cultures in response to IL-2 but not, or at lower and ineffective levels, to IL-15.
Whatever the reason for our observation, the results of the studies on the CD161 ϩ /CD56 Ϫ NK cells generated necessarily from cultures with IL-2 indicate that in vitro systems containing this cytokine are appropriate for studying the origin and significance of NK cell subsets in the peripheral blood. Likely because of the sharing of the ␤ and ␥ c signal transduction subunits of its receptor, 53,55 IL-2 substitutes for IL-15 in vitro to study NK cell differentiation in the murine system. 54 A CD161 ϩ /CD56 Ϫ NK cell subset and IL-13 ϩ NK cells have been detected, although in minor proportions, in peripheral adult and neonatal blood 19, 21 ; and NK cells producing high levels of IL-13 and IL-5, with correspondingly lower IFN-␥ levels, can be expanded/induced from peripheral NK cells. 56 Finally, although IL-2 is unlikely to be a growth factor for NK cells in physiologic conditions, it may influence differentiation of NK cells from their progenitors in the bone marrow under pathologic conditions in which IL-2-producing activated T cells are present, or in the peripheral blood during infection, once specific activated T cells have been generated.
As previously reported, 52 IL-12 alone does not support NK cell differentiation although, in concert with other growth/differentiation factors, it supports differentiation of hematopoietic progenitors (preferentially myeloid) both in vitro [57] [58] [59] [60] and in vivo, 61 and affects later stages of differentiation of the CD56 Ϫ NK cells generated in cultures with IL-2. 21, 52 The inability of IL-12 to support IL-2 and IL-15 in allowing NK cell differentiation in vitro, and the observation that NK cells are generated, although functionally impaired, in IL-12 p40 Ϫ/Ϫ mice, 62 adds to the contention that this cytokine does not participate in early steps of NK cell differentiation. The inhibitory effect of IL-12 indicates a negative regulatory effect of this cytokine. This may depend on preferential induction of differentiation or proliferation of immature myeloid cells, and may be mediated, in part, via induced TNF-␣ production and/or TNF-R1 expression. [63] [64] [65] However, neutralization of TNF-␣ or IFN-␥, and addition of either cytokine to IL-2 or IL-15 (not shown) had no significant effects on NK cell differentiation, and direct or indirect inhibitory effects of IL-12 (eg, induction of Fas/FasL and consequent apoptosis) on progenitors or differentiating NK cells cannot be excluded. For abbreviations, see Table 1 . *Cells from primary cultures of CD34 ϩ cells with Flt3-L and IL-2 from 2 independent donors (1 and 2) were cultured for 8 days in secondary culture with IL-12 (2 ng/mL), IL-2 (50 U/mL) and 50-Gy-irradiated Daudi feeder cells. CD161 ϩ /CD56 Ϫ cells from similar cultures from a third donor were prepared by sorting, after sensitization with anti-CD3, anti-CD5, and anti-CD56 mAbs. Upon reanalysis, the proportion of CD161 ϩ cells in this donor was more than 99%, with no detectable CD56 ϩ cells. Intracellular cytokines and surface phenotype (CD56 or CD56 and CD161) were analyzed simultaneously before (day 0, 3-color immunofluorescence with anti-CD3, anti-CD56 alone, or with anti-CD161, and anti-IFN-␥, anti-IL-5, or IL-13 mAbs) and at the end of the culture (day 8 or 9, 4-color immunofluorescence with anti-CD3, anti-CD56 alone, or with anti-CD161, anti-IFN-␥, and anti-IL-5 or IL-13 mAbs) on cells stimulated as in Figure 4 . Analysis was performed on gated CD3 Ϫ cells.
†All IL-5 ϩ cells were always included within the IL-13 ϩ population. ‡Figures are percent cells positive for the cytokine indicated above them. §Numbers in parentheses are the percentages of cells within the indicated cytokine ϩ population producing also the cytokines indicated in the parentheses above them.
The percentages of CD3 Ϫ /CD56 ϩ cells within total CD161 ϩ NK cells in donor 1 were 56 on day 0 and 53 on day 8; in donor 2 they were 90 on day 0 and 87 on day 8. On day 0, before secondary culture, more than 99% of the cells from donor 3 were CD3 Ϫ /CD161 ϩ /CD56 Ϫ ; these contained no detectable CD56 ϩ or IFN-␥ ϩ /IL-13 ϩ cells. After a 9-day culture, the proportion of CD161 ϩ /CD56 ϩ cells increased to 49% with IL-2 and IL-12 and Daudi and to 10% with IL-2 and IL-12 only. ¶Not done. #Not applicable (0% CD56 ϩ cells).
Our data indicate that most immature CD161 ϩ /CD56 Ϫ cells produce IL-13, and a discrete subset of them coexpresses IL-5, in the absence of IFN-␥. Interestingly, it has been recently reported that an asialoGM-1 ϩ , DX5 ϩ , non-T, non-NK/T, nonmature NK cell type found in association with immature B cells in the bone marrow 66 is responsible for protecting these cells from antigen-induced, apoptosis-mediated deletion. Given the phenotype reminiscent of the human immature IL-13 ϩ NK cells we report here, and the antiapoptotic effects of IL-13 on B cells, 67 it will be important to determine whether immature bone marrowresident NK cells play a role to control B-cell selection. Additionally, from our data, the suggestion can be made that resting IL-5 ϩ or IL-13 ϩ peripheral blood NK cells may represent NK cells that exited the bone marrow at relatively late, although not final, stages of differentiation.
A major proportion of cells with phenotype (CD56 and other differentiation antigens) and functions (IFN-␥, but not IL-13 production) of mature NK cells and, importantly, CD56 Ϫ/dim /IL-13 ϩ /IFN-␥ ϩ NK cells with intermediate phenotype, are generated from the CD161 ϩ /CD56 Ϫ cells derived from both in vitro culture models containing IL-2 after switch to culture conditions including IL-12 and B lymphoblastoid cells as feeder. This occurs both using total NK or purified CD161 ϩ /CD56 Ϫ NK cells. Also, similar numbers of cells were recovered from the cultures without feeder cells (not shown), and cytokines alone did not support significant changes in cytokine production. Thus, it is unlikely that the cells with mature or intermediate phenotype derive from expansion of minor contaminants in the original population. We favor the interpretation that type 2 and type 1 cytokine production is a functional characteristic of NK cells at distinct stages, rather than of distinct subsets of cells at an identical stage of differentiation. Unlike IL-2 21 (and IL-15, reported here), IL-12 in the presence of feeder cells promotes terminal functional differentiation of the immature CD161 ϩ / CD56 Ϫ NK cells, as previously proposed based on induced expression of IFN-␥ mRNA and CD56. 21 Unlike IFN-␥ and type 2 cytokine production, that of GM-CSF and TNF-␣ does not define distinct stages of differentiation, although the lower levels of GM-CSF detected on a per cell basis in the CD56 ϩ cells suggest its decreased production during differentiation.
Only a fraction of the CD56 ϩ NK cells from the primary cultures were induced to express IFN-␥, similar to what is observed, with interdonor variability, in peripheral blood NK cells. The observation that only a proportion of the CD161 ϩ / CD56 Ϫ cells differentiate under the appropriate conditions most likely depends on lack of additional factors. NK cell functions are impaired in vivo (decreased cytotoxicity and lower IFN-␥ production by either T or NK cells) in mice with a disrupted IL-12R ␤1 chain gene 68 and in those lacking IL-18. 69 Further functional impairment is observed in the NK1.1 (NKRP-1A, CD161) ϩ NK cells from IL-12 p40 Ϫ/Ϫ /IL-18 Ϫ/Ϫ mice, 69 paralleling our in vitro data. This suggests that together with IL-12, IL-18 (and possibly other factors) may be involved in the functional final maturation of NK cells to IFN-␥ production. It will be important to determine whether peripheral NK cells in the IL-12 p40 Ϫ/Ϫ /IL-18 Ϫ/Ϫ mice are arrested at a stage of differentiation equivalent to that of the CD161 ϩ /CD56 Ϫ NK cells reported here.
IL-12 with IL-2 or IL-15 alone (the latter 2 likely needed to support survival/proliferation) induce CD56 expression at low density and IFN-␥ in a minor proportion of the cells, without concomitant decrease in the proportion of IL-5 ϩ and IL-13 ϩ cells. The observation that most IL-13 ϩ cells under these conditions are still CD56 Ϫ supports the hypothesis that cytokines alone are incompletely effective to support differentiation of the CD161 ϩ NK cells. No significant changes were detected, at the times analyzed, in the proportion of IL-13 ϩ and IL-5 ϩ cells in cultures with IL-4 (not shown). In keeping with the data of Warren et al in mature NK cells, 20 IL-4 may support survival and/or proliferation, rather than differentiation, of the relatively immature CD161 ϩ / CD56 Ϫ NK cells.
Our data support the conclusion that the ability to produce IFN-␥ is acquired by NK cells at intermediate to late stages of differentiation, concomitant with the shut-off of the type 2 cytokines IL-5 and IL-13 specifically and irreversibly induced by IL-12 and possibly other cytokines. We have recently demonstrated that, like in the 2 culture systems that recapitulate and mimic the bone marrow environment (including culture of progenitor cells with IL-2), the CD161 ϩ /CD56 Ϫ NK cells detectable in peripheral blood produce IL-13, but not IFN-␥. These cells undergo IL-12-induced differentiation to IFN-␥ ϩ /IL-13 Ϫ /CD56 ϩ NK cells, transiting through an IL-13 ϩ /IFN-␥ ϩ stage at which the cells start expressing CD56. 70 Thus, the 2 in vitro systems dissected here will be invaluable in future studies of the cytokine-mediated and molecular regulation of the differentiation and functions of NK cells at stages preceding or following the intermediate CD161 ϩ /IL-13 ϩ stage.
